These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
566 related articles for article (PubMed ID: 19331215)
1. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient. Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215 [TBL] [Abstract][Full Text] [Related]
2. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913 [TBL] [Abstract][Full Text] [Related]
4. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516 [TBL] [Abstract][Full Text] [Related]
5. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111 [TBL] [Abstract][Full Text] [Related]
6. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H Oncology; 2006; 70(1):54-62. PubMed ID: 16446550 [TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide. Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730 [TBL] [Abstract][Full Text] [Related]
8. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643 [TBL] [Abstract][Full Text] [Related]
9. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996 [TBL] [Abstract][Full Text] [Related]
11. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853 [TBL] [Abstract][Full Text] [Related]
12. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes. Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646 [TBL] [Abstract][Full Text] [Related]
13. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882 [TBL] [Abstract][Full Text] [Related]
14. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225 [TBL] [Abstract][Full Text] [Related]
16. Characterization of cytomegalovirus pp65-HLA-A24 peptide-specific CTL lines from metastatic melanoma patients. Akiyama Y; Tai S; Komiyama M; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y Oncol Rep; 2009 Jul; 22(1):185-91. PubMed ID: 19513522 [TBL] [Abstract][Full Text] [Related]
17. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy. Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380 [TBL] [Abstract][Full Text] [Related]
18. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204 [TBL] [Abstract][Full Text] [Related]
19. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399 [TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro. Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]